Merrill rates Angiotech neutral

Angiotech Pharmaceuticals Inc. was given a neutral rating by Merrill Lynch analyst Hari Sambasivam on news the company's partner, Boston Scientific, reported quarterly Taxus sales of $572 million, compared to the analyst's estimate of $562 million. Looking ahead, significant debate is expected regarding late stent thrombosis, according to the analyst. Angiotech should be of interest to value investors since current share prices overlook the continuing cash flow from Taxus and potential for revenue growth from Contour Threads, as well as the company's pipeline. Shares of the Vancouver, B.C.-based medical technology company were up 49 cents, or 5.50%, at $9.40. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.